Shares of Theravance Biopharma were mauled in September, along with most otherbiotech stocks in general.
Does the big sell-off represent a buying opportunity? Read the presentation below to find out.
Continue Reading Below
The article Why Theravance Biopharma Inc. Fell 20% in September originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.